Loading clinical trials...
Loading clinical trials...
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors
Conditions
Interventions
AMXT1501
DFMO
Locations
4
United States
Next Oncology - Austin Midtown
Austin, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Next Oncology - San Antonio
San Antonio, Texas, United States
Virginia Cancer Center
Fairfax, Virginia, United States
Start Date
June 12, 2018
Primary Completion Date
December 30, 2022
Completion Date
April 21, 2023
Last Updated
May 25, 2023
NCT05198830
NCT05884320
NCT04929028
NCT04550494
NCT05245812
NCT06345508
Lead Sponsor
Aminex Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions